Spruce Biosciences (SPRB) Amortizatization of Intangibles (2021 - 2023)
Spruce Biosciences (SPRB) posted quarterly Amortizatization of Intangibles of $66000.0 for Q4 2023, down 29.03% year-over-year from $93000.0 in Q4 2022, and down 52.17% quarter-over-quarter from $138000.0 in Q3 2023.
Spruce Biosciences (SPRB) Amortizatization of Intangibles (2021 - 2023) Analysis & Trends
Spruce Biosciences (SPRB) has reported Amortizatization of Intangibles for 3 consecutive years, with $66000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Amortizatization of Intangibles fell 29.03% year-over-year to $66000.0; the TTM figure through Sep 2024 stood at $66000.0 (down 90.05% YoY), while the FY2023 annual figure was $636000.0, up 4075.0% from the prior year.
- Amortizatization of Intangibles declined to $66000.0 in Q4 2023 per SPRB's latest filing, from $138000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $249000.0 in Q2 2023 and bottomed at -$61000.0 in Q4 2021.
- Historically, Amortizatization of Intangibles has averaged $50200.0 across 3 years, with a median of $32500.0 in 2022.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 13900.0% in 2023 and fell as far as 29.03% in 2023.
- Spruce Biosciences' Amortizatization of Intangibles stood at -$61000.0 in 2021, then jumped by 252.46% to $93000.0 in 2022, then declined by 29.03% to $66000.0 in 2023.
- Business Quant data shows SPRB's Amortizatization of Intangibles at $66000.0 in Q4 2023, $138000.0 in Q3 2023, and $249000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 66,000.00 |
| Dec 31, 2023 | 66,000.00 |
| Sep 30, 2023 | 138,000.00 |
| Sep 30, 2023 | 138,000.00 |
| Jun 30, 2023 | 249,000.00 |
| Jun 30, 2023 | 249,000.00 |
| Mar 31, 2023 | 183,000.00 |
| Mar 31, 2023 | 183,000.00 |
| Dec 31, 2022 | 93,000.00 |
| Dec 31, 2022 | 93,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | -52,000.00 |
| Jun 30, 2022 | -52,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -61,000.00 |
| Dec 31, 2021 | -61,000.00 |
| Sep 30, 2021 | -57,000.00 |
| Sep 30, 2021 | -57,000.00 |